Rallybio (RLYB) Return on Assets (2021 - 2026)

Rallybio (RLYB) posted Return on Assets of 0.0% for Q1 2026, down 3.42% sequentially from 0.0% in Q4 2025, and up 1.0% YoY from 0.0% in Q1 2025.

Rallybio (RLYB) Return on Assets (2021 - 2026) Analysis & Trends

Rallybio has reported Return on Assets for 6 years, with the latest figure at 0.0% in Q1 2026.

Quarterly Return on Assets rose 1.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (up 1.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
Return on Assets eased to 0.0% in Q1 2026 per RLYB's latest filing, from 0.0% in the prior quarter.
Over five years, Return on Assets peaked at 0.0% in Q4 2025 and troughed at 0.01% in Q4 2024.
A 5-year average of 0.0% and a median of 0.0% in 2023 frame the typical range for Return on Assets.
The sharpest annual moves came in 2022 and 2025: Return on Assets changed 0 bps in 2022, then rose 1 bps in 2025.
Over 5 years, Return on Assets stood at 0.0% in 2022, then plunged by 44 bps to 0.01% in 2023, then declined by 30 bps to 0.01% in 2024, then soared by 83 bps to 0.0% in 2025, then decreased by 3 bps to 0.0% in 2026.
According to Business Quant data, Return on Assets over the past three periods registered 0.0%, 0.0%, and 0.0% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROA (Qtr)
1	Vertex Pharmaceuticals	138.04 Bn	130.19 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	85.58 Bn	77.59 Bn	3.93 Bn	0.00%
3	Argenx Se	64.52 Bn	59.34 Bn	1.37 Bn	-
4	Moderna	56.52 Bn	51.38 Bn	52.00 Mn	0.00%
5	BeOne Medicines	42.04 Bn	36.94 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	30.67 Bn	27.36 Bn	992.69 Mn	0.00%
7	Insmed	27.27 Bn	26.11 Bn	358.27 Mn	0.00%
8	BioNTech SE	27.14 Bn	8.75 Bn	668.28 Mn	0.00%
9	Royalty Pharma	27.12 Bn	26.28 Bn	-	0.00%
10	Rallybio	95.52 Mn	95.52 Mn	-	0.01%

Download Data